The Application of Imaging and Molecular Markers in Cancer Diagnosis and Treatment

Teng Wang

doi:10.62051/j6p6xy59

Authors

Teng Wang

DOI:

https://doi.org/10.62051/j6p6xy59

Keywords:

Radiological technology; molecular markers; imaging diagnosis; individualized treatment; multimodal image.

Abstract

Cancer is one of the leading causes of death worldwide, and its diagnosis and treatment face many challenges. In recent years, the combination of imaging techniques and molecular markers has made remarkable progress in cancer diagnosis and treatment. Imaging techniques such as CT, MRI and PET-CT can provide anatomical and functional information of tumors, while molecular markers such as EGFR and HER2 play a key role in tumor diagnosis, prognosis and treatment. However, how to effectively combine these technologies to achieve more accurate diagnosis and treatment is still a gap in research. This paper reviews the combined application of imaging technology and molecular markers in cancer diagnosis, therapeutic response monitoring and individualized therapy, analyzes the synergistic effect of multimodal imaging technology and molecular markers, and finds that it has significant advantages in early detection and individualized treatment planning. Combining imaging and molecular marker information can improve the accuracy of cancer diagnosis and guide targeted therapies. The combination of such technologies provides a new reference for precision cancer medicine in the future, but further research is still needed in the aspects of marker sensitivity and image analysis automation. In the future, the combination of new technologies such as artificial intelligence is expected to promote the development of more accurate and efficient cancer diagnosis and treatment.

Downloads

Download data is not yet available.

References

[1] World Health Organization. Cancer. 2021. https://www.who.int/health-topics/cancer#tab=tab_1.

[2] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-249.

[3] National Cancer Institute. Cancer Complexity and Heterogeneity. National Institutes of Health, 2020.

[4] Fletcher JW, Kuhl CK, Veronen R, Ruhlman M, Gonen M, Gambhir SS, Wahl RL. Recommendations on the Use of 18F-FDG PET in Oncology. Journal of Nuclear Medicine, 2008, 49(3): 480-508.

[5] Gallamini A, Rutella S, Di Raimondo F, Gloghini A, Luminari S, Tosi P, Trotter A. Early interim PET scan in Hodgkin lymphoma: where do we stand? Leukemia & Lymphoma, 2007, 48(2): 251-253.

[6] Schilsky RL, Kaye JA, Topol EJ, Murray J. Molecular Markers in Cancer: Advancing Personalized Medicine. CA: A Cancer Journal for Clinicians, 2016, 66(6): 353-369.

[7] Collins DC, Kaye JA, Schilsky RL, Topol EJ, Murray J. The Role of Molecular Markers in the Diagnosis and Treatment of Cancer. Journal of Clinical Oncology, 2017, 35(9): 883-895.

[8] Pichler BJ, Veit-Haibach P, Schwaiger M. Hybrid PET/MRI: Paving the Way for Next-Generation Imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35(6): 1174-1185.

[9] Lindner T, Giesel FL, Carlsen J, Eberhardt N, Kopp-Schneider A, Müller M. Targeting of Activated Fibroblasts for Imaging and Therapy with 68Ga-FAPI. Journal of Nuclear Medicine, 2018, 59(9): 1423-1429.

[10] Giesel FL, Becker AS, Mier W, Geyer M, Haberkorn U. 68Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of a novel fibroblast activation protein-targeted radiotracer. Journal of Nuclear Medicine, 2019, 60(3): 386-392.

[11] Boss A, Becker M, Grünwald V, Hellwig D, Schwaiger M, Pichler BJ. Hybrid PET/MRI: A Tool for Personalized Cancer Treatment. Journal of Nuclear Medicine, 2012, 53(10): 1565-1575.

[12] Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44(1): 97-110.

[13] Gallamini A, Tosi P, Rutella S, Gloghini A, Luminari S, Trotter A. The role of PET/CT in the modern management of non-Hodgkin lymphomas. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41(10): 2038-2055.

[14] Dietlein F, Schwaiger M, Pichler BJ. The future of personalized oncology: focusing on molecular imaging and its essential role in developing precision medicine in cancer care. Clinical Cancer Research, 2016, 22(21): 5467-5471.